Ferguson Wellman Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.9M Buy
77,629
+55,274
+247% +$26.5M 0.48% 52
2026
Q1
$11M Sell
22,355
-333
-1% -$181K 0.15% 97
2025
Q4
$13.1M Sell
22,688
-1,758
-7% -$994K 0.21% 70
2025
Q3
$11.9M Sell
24,446
-613
-2% -$285K 0.19% 71
2025
Q2
$10.2M Sell
25,059
-4,860
-16% -$2.03M 0.18% 73
2025
Q1
$14.9M Sell
29,919
-73,249
-71% -$39.7M 0.29% 66
2024
Q4
$53.7M Sell
103,168
-7,435
-7% -$4.09M 1.02% 29
2024
Q3
$68.4M Sell
110,603
-1,416
-1% -$838K 1.32% 23
2024
Q2
$61.9M Sell
112,019
-6,859
-6% -$3.93M 1.26% 21
2024
Q1
$69.1M Buy
118,878
+1,948
+2% +$1.09M 1.41% 20
2023
Q4
$62.1M Buy
116,930
+2,049
+2% +$992K 1.39% 19
2023
Q3
$58.1M Sell
114,881
-376
-0.3% -$200K 1.42% 19
2023
Q2
$60.1M Buy
115,257
+816
+0.7% +$440K 1.41% 19
2023
Q1
$66M Buy
114,441
+20,983
+22% +$11.8M 1.66% 14
2022
Q4
$51.5M Sell
93,458
-453
-0.5% -$240K 1.34% 23
2022
Q3
$47.6M Buy
93,911
+17,976
+24% +$10.1M 1.86% 9
2022
Q2
$41.3M Buy
75,935
+19
+0% +$10.5K 1.53% 13
2022
Q1
$44.8M Sell
75,916
-1,982
-3% -$1.14M 1.41% 20
2021
Q4
$52M Sell
77,898
-315
-0.4% -$197K 1.51% 14
2021
Q3
$44.7M Buy
78,213
+169
+0.2% +$92.8K 1.44% 19
2021
Q2
$39.4M Sell
78,044
-31,573
-29% -$14.9M 1.28% 19
2021
Q1
$50M Sell
109,617
-15,791
-13% -$7.54M 1.74% 13
2020
Q4
$58.4M Sell
125,408
-8
-0% -$3.75K 1.43% 18
2020
Q3
$55.4M Sell
125,416
-1,095
-0.9% -$452K 1.53% 17
2020
Q2
$45.8M Sell
126,511
-31,377
-20% -$10.5M 1.4% 20
2020
Q1
$44.8M Buy
157,888
+15,601
+11% +$4.92M 1.68% 15
2019
Q4
$46.2M Buy
142,287
+17
+0% +$5.16K 1.36% 18
2019
Q3
$41.4M Buy
142,270
+24
+0% +$6.87K 1.32% 19
2019
Q2
$41.8M Sell
142,246
-1,581
-1% -$435K 1.39% 13
2019
Q1
$39.4M Sell
143,827
-46,181
-24% -$11.5M 1.34% 18
2018
Q4
$42.5M Buy
190,008
+840
+0.4% +$197K 1.63% 14
2018
Q3
$46.2M Buy
189,168
+314
+0.2% +$72.2K 1.52% 16
2018
Q2
$39.1M Sell
188,854
-1,952
-1% -$414K 1.37% 16
2018
Q1
$39.4M Sell
190,806
-2,258
-1% -$474K 1.4% 16
2017
Q4
$36.7M Buy
193,064
+48,414
+33% +$9.27M 1.27% 23
2017
Q3
$27.4M Sell
144,650
-1,605
-1% -$291K 0.99% 29
2017
Q2
$25.5M Buy
146,255
+761
+0.5% +$128K 0.96% 33
2017
Q1
$22.3M Buy
145,494
+1,076
+0.7% +$164K 0.86% 36
2016
Q4
$20.4M Sell
144,418
-323
-0.2% -$47.6K 0.83% 40
2016
Q3
$23M Buy
144,741
+1,810
+1% +$279K 0.98% 33
2016
Q2
$21.1M Buy
142,931
+140,147
+5,034% +$20.7M 0.89% 40
2016
Q1
$394K Hold
2,784
0.02% 234
2015
Q4
$395K Buy
2,784
+18
+0.7% +$2.4K 0.02% 256
2015
Q3
$338K Hold
2,766
0.02% 262
2015
Q2
$359K Hold
2,766
0.01% 267
2015
Q1
$372K Sell
2,766
-21
-0.8% -$2.71K 0.02% 258
2014
Q4
$349K Hold
2,787
0.01% 266
2014
Q3
$339K Sell
2,787
-27
-1% -$3.28K 0.01% 264
2014
Q2
$332K Buy
+2,814
New +$331K 0.01% 272

Other funds holding TMO

Ferguson Wellman Capital Management's TMO Position: Q2 2026 in Review

Ferguson Wellman Capital Management increased its Thermo Fisher Scientific (TMO) stake by 247% in Q2 2026, buying an estimated $26.5M and bringing the position to 77,629 shares worth $38.9M. The position accounts for 0.48% of the portfolio, ranked #52.

Ferguson Wellman Capital Management first reported a position in TMO in Q2 2014 and has held it in 49 quarters since. The position peaked at $69.1M in Q1 2024. 838 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Ferguson Wellman Capital Management held 77,629 shares of Thermo Fisher Scientific worth $38.9M as of Q2 2026.
  • Ferguson Wellman Capital Management bought 55,274 Thermo Fisher Scientific shares in Q2 2026, an estimated $26.5M.
  • Thermo Fisher Scientific made up 0.48% of Ferguson Wellman Capital Management's portfolio in Q2 2026, its #52 holding.
  • Ferguson Wellman Capital Management first reported a position in Thermo Fisher Scientific in Q2 2014 and has held it in 49 quarters since.
  • Ferguson Wellman Capital Management's Thermo Fisher Scientific position peaked at $69.1M in Q1 2024.
  • 838 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Ferguson Wellman Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.